Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
JA Snowden, I Sánchez-Ortega… - Bone marrow …, 2022 - nature.com
For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …
Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies
In search of an ideal partner or alternative to conventional immunosuppressive agents,
rabbit anti-thymocyte globulin (ATG) and, more recently, post-transplant cyclophosphamide …
rabbit anti-thymocyte globulin (ATG) and, more recently, post-transplant cyclophosphamide …
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
AS Al-Homsi, F Cirrone, S Wo, K Cole… - Blood …, 2023 - ashpublications.org
Reducing the incidence of graft-versus-host disease (GVHD) after haploidentical
hematopoietic stem cell transplantation (HSCT) is warranted. Posttransplant …
hematopoietic stem cell transplantation (HSCT) is warranted. Posttransplant …
Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a …
Abstract Whether to choose Haploidentical (Haplo) or one-antigen mismatched unrelated
donor (1Ag-MMUD) hematopoietic cell transplantation (HCT) with post-transplant …
donor (1Ag-MMUD) hematopoietic cell transplantation (HCT) with post-transplant …
Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplantation cyclophosphamide: follow-up from a national …
The use of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease
(GVHD) prophylaxis has resulted in reductions in GVHD and improved outcomes in …
(GVHD) prophylaxis has resulted in reductions in GVHD and improved outcomes in …
Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS
C Marcoux, D Marin, J Ramdial… - American journal of …, 2023 - Wiley Online Library
Optimal donor selection is fundamental to successful allogeneic hematopoietic cell
transplantation (HCT), and donor age influences survival after both matched unrelated …
transplantation (HCT), and donor age influences survival after both matched unrelated …
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics
M Hamadani, M Ngoya, A Sureda, Q Bashir… - Blood …, 2022 - ashpublications.org
Mature T-cell lymphomas constitute the most common indication for allogeneic
hematopoietic cell transplantation (allo-HCT) of all lymphomas. Large studies evaluating …
hematopoietic cell transplantation (allo-HCT) of all lymphomas. Large studies evaluating …
HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age
Blood or marrow transplantation (BMT) outcomes using haploidentical donors (Haplo) and
posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) …
posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) …